Mechanism of Hippocampus in treatment of knee osteoarthritis based on network pharmacology, molecular docking, and experimental verification.
10.19540/j.cnki.cjcmm.20250326.501
- Author:
Tao ZHUO
1
;
Guo-Wei WANG
1
;
Si-Xian WU
1
;
Quan-Wei ZHENG
1
;
Yi HE
1
;
Jian-Hang LIU
2
Author Information
1. Guangxi University of Chinese Medicine Nanning 530001, China.
2. Beihai Hospital of Chinese Medicine,Beihai Hospital Affiliated to Guangxi University of Chinese Medicine Beihai 536000, China.
- Publication Type:Journal Article
- Keywords:
Hippocampus;
IL-17 signaling pathway;
knee osteoarthritis;
molecular docking;
network pharmacology
- MeSH:
Animals;
Molecular Docking Simulation;
Rats;
Drugs, Chinese Herbal/administration & dosage*;
Network Pharmacology;
Male;
Osteoarthritis, Knee/metabolism*;
Rats, Sprague-Dawley;
Signal Transduction/drug effects*;
Humans;
Interleukin-17/metabolism*;
Tumor Necrosis Factor-alpha/metabolism*;
Disease Models, Animal;
Hippocampus/chemistry*
- From:
China Journal of Chinese Materia Medica
2025;50(14):4026-4036
- CountryChina
- Language:Chinese
-
Abstract:
This study predicts the potential mechanism of Hippocampus in the treatment of knee osteoarthritis(KOA) through network pharmacology, with preliminary verification using molecular docking and animal experiments. The database was used to screen the active chemical components of Hippocampus and the targets of KOA, and Gene Ontology(GO) functional analysis, Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis, and molecular docking were performed on the relevant core targets to preliminarily explore the potential targets and mechanisms of Hippocampus in the treatment of KOA. A rat KOA model was constructed by intra-articular injection of sodium iodoacetate, and the rats were intervened with different doses of Hippocampus decoction and celecoxib. The expression of relevant targets was detected through hematoxylin-eosin(HE) staining, enzyme-linked immunosorbent assay(ELISA), RT-qPCR, and Western blot to further validate the network pharmacology results. A total of 23 drug-like components of the Hippocampus were screened, and 128 common targets with KOA were identified, involving interleukin-17(IL-17) signaling pathway, transcription factor(FoxO) signaling pathway, tumor necrosis factor(TNF) signaling pathway. Molecular docking results showed that the screened core chemical components exhibited good affinity with key targets. HE staining demonstrated that Hippocampus improved the morphology of the cartilage layer. ELISA confirmed that Hippocampus significantly reduced the levels of IL-6 and TNF-α in the serum of KOA rats. Western blot and RT-qPCR analysis showed that Hippocampus significantly reduced the expression of IL-6, TNF-α, matrix metalloproteinase(MMP) 13, IL-17A, nuclear factor κB activator 1(ACT1), tumor necrosis factor receptor-associated factor 6(TRAF6) and nuclear factor κB(NF-κB) in cartilage tissue. The results suggest that Hippocampus can alleviate the degree of joint damage in the KOA rat model induced by sodium iodoacetate. The mechanism of action is related to the inhibition of the IL-17 signaling pathway, reduction of inflammation, and inhibition of extracellular matrix(ECM) degradation.
